Clinical Trial Update: Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC

View source ↗

Summary

Expanded Access update for mifomelatide in adults with advanced pancreatic ductal adenocarcinoma to address cancer cachexia; the program is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Cachexia
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Mifomelatide (mifomelatide)

Snippet

Sponsor: Endevica Bio | Conditions: Pancreatic Ductal Adenocarcinoma (mPDAC), Unresectable Pancreatic Ductal Adenocarcinoma | Status: NO_LONGER_AVAILABLE